Cover Image
市場調查報告書

DURECT Corporation : 產品平台分析

DURECT Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256097
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
DURECT Corporation : 產品平台分析 DURECT Corporation - Product Pipeline Review - 2015
出版日期: 2015年08月26日 內容資訊: 英文 35 Pages
簡介

DURECT Corporation是專門的製藥公司,正在開發基於獨家藥物遞送技術平台治療慢性衰弱病用的製劑系統。該公司同時也在開發生物科技產品,以及製造滲透壓幫浦和生物分解性高分子等。

本報告提供DURECT Corporation 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

DURECT Corporation 基本資料

  • DURECT Corporation 概要
  • 主要資訊
  • 企業資料

DURECT Corporation:R&D概要

  • 主要的治療範圍

DURECT Corporation:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

DURECT Corporation:開發中產品概況

  • 最後階段的開發中產品
    • 申請不受理/被撤消的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式

DURECT Corporation:藥物簡介

  • bupivacaine hydrochloride SR
  • methylphenidate hydrochloride SR
  • sufentanil citrate
  • DUR-928

DURECT Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

DURECT Corporation:最近的開發平台趨勢

DURECT Corporation:暫停中的計劃

DURECT Corporation:企業發表

DURECT Corporation:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07485CDB

Summary

Global Markets Direct's, 'DURECT Corporation - Product Pipeline Review - 2015', provides an overview of the DURECT Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of DURECT Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of DURECT Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of DURECT Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the DURECT Corporation's pipeline products

Reasons to buy

  • Evaluate DURECT Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of DURECT Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the DURECT Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of DURECT Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of DURECT Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of DURECT Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • DURECT Corporation Snapshot
    • DURECT Corporation Overview
    • Key Information
    • Key Facts
  • DURECT Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • DURECT Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • DURECT Corporation - Pipeline Products Glance
    • DURECT Corporation - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • DURECT Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • DURECT Corporation - Drug Profiles
    • bupivacaine hydrochloride SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methylphenidate hydrochloride SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sufentanil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DUR-928
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • DURECT Corporation - Pipeline Analysis
    • DURECT Corporation - Pipeline Products by Target
    • DURECT Corporation - Pipeline Products by Route of Administration
    • DURECT Corporation - Pipeline Products by Molecule Type
    • DURECT Corporation - Pipeline Products by Mechanism of Action
  • DURECT Corporation - Recent Pipeline Updates
  • DURECT Corporation - Dormant Projects
  • DURECT Corporation - Company Statement
  • DURECT Corporation - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • DURECT Corporation, Key Information
  • DURECT Corporation, Key Facts
  • DURECT Corporation - Pipeline by Indication, 2015
  • DURECT Corporation - Pipeline by Stage of Development, 2015
  • DURECT Corporation - Monotherapy Products in Pipeline, 2015
  • DURECT Corporation - Partnered Products in Pipeline, 2015
  • DURECT Corporation - Partnered Products/ Combination Treatment Modalities, 2015
  • DURECT Corporation - Out-Licensed Products in Pipeline, 2015
  • DURECT Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • DURECT Corporation - Filing rejected/Withdrawn, 2015
  • DURECT Corporation - Phase III, 2015
  • DURECT Corporation - Phase II, 2015
  • DURECT Corporation - Phase I, 2015
  • DURECT Corporation - Pipeline by Target, 2015
  • DURECT Corporation - Pipeline by Route of Administration, 2015
  • DURECT Corporation - Pipeline by Molecule Type, 2015
  • DURECT Corporation - Pipeline Products by Mechanism of Action, 2015
  • DURECT Corporation - Recent Pipeline Updates, 2015
  • DURECT Corporation - Dormant Developmental Projects,2015

List of Figures

  • DURECT Corporation - Pipeline by Top 10 Indication, 2015
  • DURECT Corporation - Pipeline by Stage of Development, 2015
  • DURECT Corporation - Monotherapy Products in Pipeline, 2015
  • DURECT Corporation - Out-Licensed Products in Pipeline, 2015
  • DURECT Corporation - Pipeline by Top 10 Target, 2015
  • DURECT Corporation - Pipeline by Top 10 Route of Administration, 2015
  • DURECT Corporation - Pipeline by Top 10 Molecule Type, 2015
  • DURECT Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top